Hyaluronidase/Pembrolizumab - Merck
Alternative Names: MK-3475/MK-5180; MK-3475A; MK-5180/MK-3475; Pembrolizumab + hyaluronidase subcutaneous - Merck; Pembrolizumab/Hyaluronidase - Merck; Pembrolizumab/MK-5180; Recombinant human hyaluronidase and pembrolizumab - MerckLatest Information Update: 29 Nov 2024
Price :
$50 *
At a glance
- Originator Merck Sharp & Dohme
- Class Antineoplastics; Glycoside hydrolases; Immunotherapies; Monoclonal antibodies; Polysaccharide lyases; Small molecules; Tumour-agnostic therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Non-small cell lung cancer
- Phase II Diffuse large B cell lymphoma; Hodgkin's disease; Malignant melanoma; Renal cell carcinoma; Squamous cell cancer
- No development reported Solid tumours
Most Recent Events
- 21 Nov 2024 Phase-III clinical trials in Non-small cell lung cancer (Metastatic disease, First-line therapy) in South Korea (SC) (NCT06698042)
- 21 Nov 2024 Merck Sharp & Dohme initiates phase-III clinical trials in Non-small cell lung cancer (Metastatic disease, First-line therapy) in Poland, Romania and Spain (SC) (NCT06698042)
- 20 Nov 2024 Merck Sharp & Dohme plans a phase III trial for Non-small cell lung cancer (Metastatic disease, First-line therapy) in South Korea, Poland, Romania (SC) (NCT06698042)